Currently holds a position at Apellis Pharmaceuticals Inc
Position | Company | Period |
---|---|---|
General Counsel, Vice President of Corporate Development | Apellis Pharmaceuticals Inc | Jan. 1, 2014 - |
Search
Notification date | Transaction date | B/S Transaction type |
Nb. shares Price Value |
Number of shares | Price | Total value | Details | |
---|---|---|---|---|---|---|---|---|
2024-02-13 | 2024-02-12 |
Apellis Pharmaceuticals Inc
(APLS)
|
S Sale |
781
-0.7%
67.7752,926 USD |
781 -0.7% | 67.77 | 52,926 USD | |
2024-01-31 | 2024-01-29 |
Apellis Pharmaceuticals Inc
(APLS)
|
S Sale |
906
-0.9%
64.1458,109 USD |
906 -0.9% | 64.14 | 58,109 USD | |
2024-01-23 | 2024-01-22 |
Apellis Pharmaceuticals Inc
(APLS)
|
S Sale |
4,184
-3.8%
65.00271,943 USD |
4,184 -3.8% | 65.00 | 271,943 USD | |
2024-01-17 | 2024-01-16 |
Apellis Pharmaceuticals Inc
(APLS)
|
S Sale |
4,240
-3.7%
66.81283,268 USD |
4,240 -3.7% | 66.81 | 283,268 USD | |
2023-12-20 | 2023-12-19 |
Apellis Pharmaceuticals Inc
(APLS)
|
S Sale |
2,300
-2.5%
57.38131,980 USD |
2,300 -2.5% | 57.38 | 131,980 USD | |
2023-12-20 | 2023-12-19 |
Apellis Pharmaceuticals Inc
(APLS)
|
S Sale |
1,605
-1.7%
57.0091,492 USD |
1,605 -1.7% | 57.00 | 91,492 USD | |
2023-07-06 | 2023-07-03 |
Apellis Pharmaceuticals Inc
(APLS)
|
PS Planned sale |
8,510
-9.0%
89.98765,730 USD |
8,510 -9.0% | 89.98 | 765,730 USD | |
2022-06-23 | 2022-06-22 |
Apellis Pharmaceuticals Inc
(APLS)
|
S Sale |
10,000
-8.0%
44.51445,140 USD |
10,000 -8.0% | 44.51 | 445,140 USD | |
2022-04-27 | 2022-04-25 |
Apellis Pharmaceuticals Inc
(APLS)
|
PS Planned sale |
5,000
-3.8%
50.00250,000 USD |
5,000 -3.8% | 50.00 | 250,000 USD | |
2021-12-23 | 2021-12-22 |
Apellis Pharmaceuticals Inc
(APLS)
|
S Sale |
300
-0.3%
48.5814,573 USD |
300 -0.3% | 48.58 | 14,573 USD | |
2021-12-23 | 2021-12-22 |
Apellis Pharmaceuticals Inc
(APLS)
|
S Sale |
5,097
-4.5%
47.86243,917 USD |
5,097 -4.5% | 47.86 | 243,917 USD | |
2021-12-23 | 2021-12-22 |
Apellis Pharmaceuticals Inc
(APLS)
|
S Sale |
5,174
-4.7%
47.72246,883 USD |
5,174 -4.7% | 47.72 | 246,883 USD | |
2020-12-15 | 2020-12-14 |
Apellis Pharmaceuticals Inc
(APLS)
|
S Sale |
200
-0.5%
55.9111,182 USD |
200 -0.5% | 55.91 | 11,182 USD | |
2020-12-15 | 2020-12-14 |
Apellis Pharmaceuticals Inc
(APLS)
|
S Sale |
900
-2.0%
55.0049,501 USD |
900 -2.0% | 55.00 | 49,501 USD | |
2020-12-15 | 2020-12-14 |
Apellis Pharmaceuticals Inc
(APLS)
|
S Sale |
900
-2.0%
53.8648,475 USD |
900 -2.0% | 53.86 | 48,475 USD | |
2020-12-15 | 2020-12-14 |
Apellis Pharmaceuticals Inc
(APLS)
|
S Sale |
1,163
-2.5%
52.7361,322 USD |
1,163 -2.5% | 52.73 | 61,322 USD | |
2020-12-15 | 2020-12-14 |
Apellis Pharmaceuticals Inc
(APLS)
|
S Sale |
2,526
-5.1%
51.32129,624 USD |
2,526 -5.1% | 51.32 | 129,624 USD | |
2020-12-15 | 2020-12-14 |
Apellis Pharmaceuticals Inc
(APLS)
|
S Sale |
2,709
-5.2%
50.61137,094 USD |
2,709 -5.2% | 50.61 | 137,094 USD | |
2020-12-15 | 2020-12-11 |
Apellis Pharmaceuticals Inc
(APLS)
|
S Sale |
9,935
-18.6%
50.00496,750 USD |
9,935 -18.6% | 50.00 | 496,750 USD | |
2020-02-12 | 2020-02-10 |
Apellis Pharmaceuticals Inc
(APLS)
|
PS Planned sale |
5,000
-12.4%
44.50222,500 USD |
5,000 -12.4% | 44.50 | 222,500 USD | |
2020-01-28 | 2020-01-27 |
Apellis Pharmaceuticals Inc
(APLS)
|
PS Planned sale |
3,000
-13.6%
40.47121,401 USD |
3,000 -13.6% | 40.47 | 121,401 USD |